• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

    4.970 -0.020 (-0.40%)
    Streaming Delayed Price Updated: 2:52 PM EDT, Sep 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,428,213
    Open 4.970
    Bid (Size) 4.960 (3,800)
    Ask (Size) 4.970 (1,300)
    Prev. Close 4.990
    Today's Range 4.800 - 5.030
    52wk Range 3.100 - 7.300
    Shares Outstanding 64,465,037
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    These 3 Risky Stocks Could Be Sitting on 100% Upside ↗
    Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks. 
    Via MarketBeat
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -5.3%
    -5.3%
    1 Month
    -12.7%
    -12.7%
    3 Month
    -26.2%
    -26.2%
    6 Month
    +22.1%
    +22.1%
    1 Year
    +57.3%
    +57.3%

    More News

    Read More
    News headline image
    Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call ↗
    Via The Motley Fool
    Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗
    Via Chartmill
    Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗
    Via Chartmill
    News headline image
    Taysha Gene Therapies Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha (TSHA) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
    Via The Motley Fool
    News headline image
    Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Taysha Gene Therapies, Inc. - Common Stock publicly traded?
    Yes, Taysha Gene Therapies, Inc. - Common Stock is publicly traded.
    What exchange does Taysha Gene Therapies, Inc. - Common Stock trade on?
    Taysha Gene Therapies, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Taysha Gene Therapies, Inc. - Common Stock?
    The ticker symbol for Taysha Gene Therapies, Inc. - Common Stock is TSHA on the Nasdaq Stock Market
    What is the current price of Taysha Gene Therapies, Inc. - Common Stock?
    The current price of Taysha Gene Therapies, Inc. - Common Stock is 4.970
    When was Taysha Gene Therapies, Inc. - Common Stock last traded?
    The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 09/29/26 02:52 PM ET
    What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?
    The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 320.39M
    How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?
    Taysha Gene Therapies, Inc. - Common Stock has 320M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.